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Accelerated lean body mass loss in incident chronic dialysis
patients with diabetes mellitus.
Background. End-stage renal disease (ESRD) patients dis-
play a higher incidence of poor nutritional status and are at high
risk of hospitalization and death. Patients on renal replacement
therapy (RRT) with a primary diagnosis of diabetes mellitus
have the lowest survival rates along with highest hospitaliza-
tion incidence.
Methods. In this study, we examined the importance of di-
abetes mellitus along with certain demographic and clinical
variables in predicting the change in lean body mass (LBM)
by dual-energy x-ray absorptiometry (DEXA), as a surrogate
marker of somatic protein stores, in 142 incident ESRD patients
(91 males, 52.8 ± 1.0 years, 74.2 ± 1.2 kg body weight) among
which 34 had diabetes mellitus (19 insulin-dependent and 15
noninsulin dependent).
Results. Our results show that patients with diabetes mel-
litus had significantly accelerated loss of LBM compared to
nondiabetic patients during the first year of RRT (3.4 ±
0.6 kg vs. 1.1 ± 0.2 kg) (P < 0.05). Multivariate linear regres-
sion analyses revealed that the presence of diabetes mellitus was
the strongest predictor of LBM loss independently of several
clinically-relevant variables such as age, gender, serum albumin,
presence of malnutrition, presence of inflammation, and RRT
modality.
Conclusion. We conclude that the presence of diabetes mel-
litus is the most significant independent predictor of LBM loss
in renal replacement therapy patients, providing a potential ex-
planation as to why ESRD patients with diabetes mellitus are
more prone to muscle wasting.
The number of end-stage renal disease (ESRD) pa-
tients initiating renal replacement therapy (RRT) with
a diagnosis of diabetes mellitus is alarmingly increasing,
with an incidence of about 60% [1]. Chronic RRT pa-
tients with a primary diagnosis of diabetes mellitus have
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the lowest survival rates along with highest hospitaliza-
tion incidence [2].
Several factors can predispose RRT patients to worse
clinical outcomes. Malnutrition (i.e., wasting), a comorbid
condition known to be associated with increased risk of
hospitalization and death risk in RRT patients, is shown
to be at higher prevalence in diabetic chronic RRT pa-
tients in cross-sectional studies, especially in patients on
hemodialysis [2]. Importantly, the coexistence of wasting
and diabetes mellitus synergistically increases the death
risk in chronic RRT patients. Currently, there are only a
limited number of studies examining the relationship be-
tween diabetes mellitus and malnutrition in RRT patients
on a prospective longitudinal basis.
Based on these observations, we hypothesized that the
presence of diabetes mellitus leads to loss of muscular
mass (sarcopenia) in RRT patients, a potential mech-
anism leading to increased risk of hospitalization and
death. To test this hypothesis, we followed changes in
body composition [lean body mass (LBM) and fat mass
(FM)] by dual-energy x-ray absorptiometry (DEXA) in
142 incident RRT patients (34 with diabetes mellitus) dur-
ing the initial 12 months of RRT. We associated these
changes with certain demographic and clinical variables
in order to define significant determinants of any poten-
tial changes in nutritional status overtime.
METHODS
Patients
Patients were recruited from the Nephrology clinic at
the Karolinska University Hospital at Huddinge, Stock-
holm, Sweden. Inclusion criteria consisted of ESRD pa-
tients initiating RRT, and exclusion criteria were age
>70 years, overt infectious disease, and unwillingness to
participate in the study. Most patients were on antihy-
pertensive medications as well as other commonly used
drugs in ESRD, such as phosphate and potassium binders
(sodium polystyrene sulphonate), diuretics, and vitamin
B, C, and D supplementation. All patients had Kt/V ≥1.2
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Table 1. Study variables in patients who completed the study and
patients who dropped out
Completed Dropped out
(N = 142) (N = 123)
Clinical characteristics
Male gender 91 (64%) 76 (62%)
Age years 52.8 ± 1.0 52.1 ± 1.1
Subjective Global Assessment ≥2
(malnourished)
46 (32%) 45 (36%)
Presence of cardiovascular disease 40 (28%) 51 (41%)a
Presence of diabetes mellitus 34 (24%) 46 (37%)a
Laboratory values
Serum albumin g/L 33.9 ± 0.5 32.0 ± 0.6a
Serum C-reactive protein ≥10 mg/L
(inflamed)
45 (32%) 54 (44%)a
Glomerular filtration rate mL/min 7.1 ± 0.2 7.1 ± 0.3
Albuminuria mg/24 hoursb 2767 ± 290 3326 ± 486
Body composition
Body weight kg 74.2 ± 1.2 71.7 ± 1.4
Body mass index kg/m2 24.9 ± 0.4 24.4 ± 0.4
Fat mass kg 22.2 ± 0.8 20.6 ± 0.1
Lean body mass kg 50.1 ± 0.8 48.7 ± 1.1
aP < 0.05 for completed vs. dropped out.
bN = 129.
and efforts were made to keep total bicarbonate con-
centrations above 22 mmol/L. The Ethics Committee of
the Karolinska Institutet approved the study protocol at
Huddinge University Hospital, Stockholm, and informed
consent was obtained from the patients. Patient charac-
teristics are shown in Table 1.
Design
This is a subset analysis of an ongoing prospective study
and part of the data has been already published [3]. The
purpose of the original cohort was to study risk factors
for the development of malnutrition and cardiovascular
disease in incident ESRD patients starting dialysis. The
time period of enrollment for this cohort was June 1995 to
April 2003. The objective of this subanalysis was to com-
pare body composition trends in diabetics and nondiabet-
ics over the first year of renal replacement therapy, and
associate these changes with other clinically relevant clin-
ical data. After reviewing inclusion and exclusion criteria,
265 ESRD patients (167 men) (63%) with a mean age of
52 ± 12 years old were evaluated shortly before initiation
of RRT [mean glomerular filtration rate (GFR) of 7.1 ±
0.2 mL/min]. Eighty of the patients (30%) had a diagnosis
of diabetes mellitus at initiation of study. One hundred
and forty-two patients (34 were diabetics) completed the
12-month evaluation of LBM and were included in the
final analyses. Reasons for dropout before the second
12-month assessment of DEXA included death (N =
35), renal transplantation (N = 29), and a variety of dif-
ferent reasons for loss of follow-up (N = 59), including
unwillingness or impossibility to come to clinics for a
second DEXA measurement, technical problems or un-
availability of the DEXA machine, and patient transfer
to another dialysis facility. Of the 142 patients who com-
pleted the 12-month DEXA evaluation, 82 started peri-
toneal dialysis, whereas 60 patients started hemodialy-
sis. Hemodialysis patients were treated by conventional
bicarbonate-buffered dialysate using either polyamide,
cellulose acetate, or hemophane filters, whereas peri-
toneal dialysis patients were on a four to five exchanges
per day schedule with standard dialysis bags.
Venous blood was collected after an overnight fast, dur-
ing usual clinic visits that occurred shortly before initia-
tion of RRT. The samples were kept frozen in −70◦C
until analysis. C-reactive protein (CRP) was measured
using nephelometry, and serum albumin by bromocresol
purple at the Department of Clinical Chemistry at Hud-
dinge University Hospital. Levels of CRP were quantified
above 10 mg/L, but not below 10 mg/L. Therefore, levels
of CRP are presented in this manuscript in two categories;
lower or greater than 10 mg/L. This cutoff level has been
shown to reliably predict clinical outcomes in congestive
heart disease patients [4]. Subjective global assessment
(SGA) was assessed by a specially trained renal nurse at
baseline to obtain an overall clinical estimate of malnu-
trition [5]. The SGA included six subjective assessments,
three based on the patient’s history of weight loss, inci-
dence of anorexia, and incidence of vomiting, and three
based on the physician’s grading of muscle wasting, pres-
ence of edema, and loss of subcutaneous fat. Scores were
coded according to a 4-point graded scale (1, no malnutri-
tion; 2, mild malnutrition; 3, moderate malnutrition; and
4, severe malnutrition) [6]. Because grades 3 and 4 were
uncommon in this study population, we have regrouped
patients into group 1 (no malnutrition), and group 2 (pres-
ence of mild to severe malnutrition). LBM and FM were
estimated by DEXA at baseline and about 12 months
after initiation of RRT, using the DPX-L device (Lunar
Corp., Madison, WI, USA). Forty of the patients that
completed the 12-month DEXA evaluation had a clin-
ical history of cerebrovascular, cardiovascular, and/or
peripheral vascular disease (grouped as CVD). Of the
40 patients, 12 had suffered from cerebrovascular disease
(stroke), 34 of cardiovascular disease (acute myocardial
infarction, angina pectoris or patients who had under-
gone coronary artery bypass surgery), 15 had a history of
peripheral ischemic atherosclerotic vascular disease, and
one patient had a history of an aortic aneurysm.
Statistical analysis
The primary outcome in this study was the continu-
ous variable LBM loss (LBM at about 12 months minus
LBM at baseline). The hypothesis to be tested was that
nondiabetic patients display more significant LBM loss
compared to nondiabetes mellitus patients with ESRD
during the first year of RRT. We initially compared base-
line data between diabetes mellitus and nondiabetes mel-
litus patients, as well as between patients who completed
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the study and patients who have dropped out, by using the
Student t test for normally distributed variables and the
Mann-Whitney U test for nonnormally distributed vari-
ables. Comparisons between categoric variables between
groups were completed by the chi-square test. Compar-
isons between baseline and 12-month period data were
completed with the paired t test for normally distributed
data and the Wilcoxon signed-rank test for nonnormally
distributed data. Identification of predictors of LBM loss
was carried out by simple and multiple linear regression
analyses. Multivariate linear regression was carried out,
including clinically significant confounders to the depen-
dent variable LBM loss (in this manuscript age, gender,
RRT modality, serum albumin, inflammation, malnutri-
tion, and the presence of diabetes mellitus). We further
analyzed data in a backward elimination procedure, when
the variables with the smallest partial correlation with the
dependent variable were sequentially considered for re-
moval, until no variables in the equation satisfied the re-
moval criteria. All tests were two-sided and a significance
level of less than 0.05 was accepted to reject the null hy-
pothesis of no difference between means. The statistical
software package SPSS version 13.0 (Chicago, IL, USA)
was used for all analyses.
RESULTS
Differences between patients that did or did not complete
the 12-month evaluation
In order to examine whether patients who did not com-
plete the 12-month DEXA evaluation were a selected
group of patients, we compared study variables between
the two groups. As expected, patients who did not com-
plete the 12-month evaluation period had higher propor-
tions of presence of CVD (41% vs. 28%) (P < 0.05),
diabetes mellitus (37% vs. 23%) (P < 0.05), and inflam-
mation (CRP ≥10 mg/L) (44% vs. 32%) (P < 0.05). In
addition, serum albumin levels were significantly lower
in patients who did not complete compared to those who
completed the study (32.0 ± 0.6 g/L vs. 33.9 ± 0.5 g/L)
(P < 0.05).
Differences between diabetics and nondiabetics
Eighty patients had a diagnosis of diabetes mellitus at
entry of study and 34 completed the 12-month evaluation
[19 initially were insulin-dependent (IDDM) and 15 ini-
tially were noninsulin-dependent (NIDDM) diabetics].
We compared baseline characteristics between diabet-
ics and nondiabetics who had completed the study. As
shown in Table 2, diabetes mellitus patients had signifi-
cantly higher glucose levels (180 ± 25 mg/dL vs. 100 ±
3 mg/dL) (P < 0.05), marginally significantly higher
plasma insulin levels (26.6 ± 3.3 lU/mL vs. 19.8 ±
1.3 lU/mL) (P = 0.06), and significantly higher
hemoglobin A1c (HbA1c) (6.8 ± 0.3% vs. 5.1 ± 0.1%)
(P < 0.05), lower serum albumin levels (31.9 ± 0.9 g/L
vs. 34.5 ± 0.5 g/L) (P < 0.05) along with greater albu-
minuria (N = 21 for diabetes mellitus patients) (4352 ±
634 mg/24 hours vs. 2203 ± 293 mg/24 hours) (P < 0.05). A
higher proportion of diabetes mellitus patients had diag-
nosis of malnutrition by SGA compared with nondiabetes
mellitus patients, although this difference did not reach
statistical significance (44% vs. 29%) (P = 0.07). With
regards to body composition, diabetes mellitus patients
had greater body weight (81.7 ± 2.7 kg vs. 71.8 ± 1.3 kg)
(P < 0.05), body mass index (BMI) (27.0 ± 0.9 kg/m2 vs.
24.2 ± 0.4 kg/m2) (P < 0.05), and LBM (55.2 ± 1.6 kg
vs. 48.5 ± 1.0 kg) (P < 0.05) at start of RRT, compared
to nondiabetes mellitus. There were more males in the
diabetes mellitus group (76% vs. 60%) (P < 0.05). The
other baseline variables were not different between dia-
betes mellitus and nondiabetes mellitus patients. We also
looked at the comparison between IDDM (N = 19) and
NIDDM (N = 15) patients who completed the study. As
expected, NIDDM patients were older than IDDM pa-
tients (61.3 ± 2.3 years vs. 49.8 ± 2.9 years) (P < 0.05),
and displayed higher BMI (29.0 ± 1.2 kg/m2 vs. 25.4 ±
1.2 kg/m2) (P < 0.05). Twenty-four–hour creatinine ex-
cretion (N = 132) was used to estimate basal LBM by
creatinine kinetics (41.4 ± 1.6 kg in nondiabetic patients
and 43.3 ± 1.2 kg in diabetic patients). As expected, a
strong positive association (R = 0.61; P < 0.0001) was
observed between basal LBM calculated by creatinine
kinetics and LBM assessed by DEXA.
Body composition changes
When analyzing the 142 patients who completed the
12-month evaluation, we observed statistically significant
changes in body composition (LBM and FM). Whereas
BMI and body weight did not change significantly during
the study period, there was a loss of 1.6 kg in LBM and
a gain of 1.6 kg in FM. Table 3 depicts the differences
in study variables in patients grouped as subjects who
lost LBM compared to those who gained LBM at the
12-month follow-up. As can be seen, LBM at baseline
was significantly different between the two groups (51.7
± 1.0 kg vs. 46.1 ± 1.6 kg) (P < 0.05), which was also true
for the diabetic patients (56.8 ± 1.6 kg vs. 46.0 ± 2.8 kg)
(P < 0.05). In the group of patients who lost LBM, there
was a significantly higher proportion of patients with dia-
betes mellitus (27% vs. 12%) (P < 0.05), and a tendency,
although not significant, for higher proportions of CVD
(32% vs. 17%) (P = 0.06), and high CRP levels (36%
vs. 20%) (P = 0.06) in the group who lost LBM. When
data were compared for diabetes mellitus and nondia-
betes mellitus patients, we observed significant LBM loss
in both groups but at a much greater extent in diabetes
mellitus patients (1.1 ± 0.2 kg for nondiabetes mellitus
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Table 2. Baseline demographic, nutritional characteristics and biochemical parameters of the study population who completed the 1-year
evaluation (N = 142) at baseline
Diabetes mellitus
All IDDM NIDDM Nondiabetes mellitus
(N = 34) (N = 19) (N = 15) (N = 108)
Clinical characteristics
Male gender 26 (76%) 14 (74%) 12 (86%) 65 (60%)a
Age years 54.9 ± 1.1 49.8 ± 2.9 61.3 ± 2.3b 52.1 ± 1.1
Subjective Global Assessment ≥ 2 (malnourished) 15 (44%) 10 (53%) 5 (33%) 31 (29%)
Laboratory values
Fasting serum glucose mg/dL 180 ± 25 216 ± 43 139 ± 17 100 ± 3a
Hemoglobin A1c% 6.8 ± 0.3 7.1 ± 0.4 6.2 ± 0.3 5.1 ± 0.1a
Plasma insulin lU/mL 26.6 ± 3.3 22.2 ± 2.8 31.6 ± 6.2 19.8 ± 1.3
Serum albumin g/L 31.9 ± 0.9 31.7 ± 1.5 32.3 ± 1.0 34.5 ± 0.5a
Serum C-reactive protein ≥10 mg/L 11 (32%) 6 (31%) 5 (33%) 34 (31%)
(inflamed)
Glomerular filtration rate mL/min 7.5 ± 0.4 7.3 ± 0.4 7.4 ± 1.0 7.0 ± 0.3
Albuminuria mg/24 hoursc 4352 ± 634 4953 ± 935 3806 ± 871 2203 ± 293a
Body composition
Body weight kg 81.7 ± 2.7 77.1 ± 3.6 87.6 ± 3.8 71.8 ± 1.3a
Body mass index kg/m2 27.0 ± 0.9 25.4 ± 1.2 29.0 ± 1.2b 24.2 ± 0.4a
Fat mass kg 24.1 ± 1.7 21.3 ± 1.8 27.5 ± 2.9 21.6 ± 0.9
Lean body mass kg 55.2 ± 1.6 53.7 ± 2.2 57.2 ± 2.3 48.5 ± 1.0a
Values are absolute numbers and percentage or means ± SEM. Abbreviations: IDDM, insulin-dependent diabetes mellitus; NIDDM, noninsulin-dependent diabetes
mellitus.
aP < 0.05 for all diabetes mellitus vs. nondiabetes mellitus.
bP < 0.05 for IDDM vs. NIDDM.
cN = 21 for diabetes mellitus and 59 for nondiabetes mellitus.
Table 3. Baseline study variables in patients who lost lean body mass (LBM) compared to those who gained LBM during 12 months of renal
replacement therapy (RRT)
LBM loss (N = 102) LBM gain (N = 40)
Clinical characteristics
Male gender 67 (65%) 24 (60%)
Age years 53.2 ± 1.2 51.8 ± 1.9
Subjective Global Assessment ≥2 (malnourished) 31 (30%) 15 (37%)
Presence of cardiovascular disease 33 (32%) 7 (17%)
Presence of diabetes mellitus 28 (27%) 5 (12%)a
Insulin-dependent diabetes mellitus 16 (57% of diabetes mellitus) 3 (60% of diabetes mellitus)
Laboratory values
Serum albumin g/L 33.4 ± 0.5 35.1 ± 0.9
Serum C-reactive protein ≥10 mg/L 37 (36%) 8 (20%)
Glomerular filtration rate mL/min 7.1 ± 0.3 7.1 ± 0.4
Albuminuria mg/24 hoursb 3079 ± 378 2188 ± 433
Total bicarbonate mmol/L 25.7 ± 4.1 25.3 ± 3.7
Body composition
Body weight kg 75.5 ± 1.5 70.9 ± 2.1
Body mass index kg/m2 25.1 ± 0.4 24.3 ± 0.6
Fat mass kg 21.7 ± 0.9 23.3 ± 1.6
Lean body mass kg 51.7 ± 1.0 46.1 ± 1.6a
aP < 0.05 for lean body mass loss vs. lean body mass gain.
bN = 80.
patients and 3.4 ± 0.6 kg for diabetes mellitus patients)
(P < 0.05) (Fig. 1).
Predictors of LBM changes by multivariate analysis
In order to identify predictors of LBM loss in the study
population, we performed multivariate linear regression
analyses. In an initial model, including variables of clin-
ical relevance to the dependent variable LBM loss [age,
gender, serum albumin, malnutrition (determined by
SGA ≥2), inflammation (determined by CRP ≥10 mg/L),
RRT modality (peritoneal dialysis or hemodialysis), and
the presence of diabetes mellitus], the presence of dia-
betes mellitus revealed to be the strongest predictor of
LBM loss, independent of all the above-mentioned con-
founders, as shown in Table 4. We also looked at the
predictors in a backward elimination procedure, initially
including all the above-mentioned variables. This proce-
dure resulted in the exclusion of four of the variables that
we considered clinically relevant, starting with the least
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Fig. 1. Scatter plots grouped by nondiabetic (non-DM) and diabetic
(DM) patients, showing individual lean body mass (LBM) loss in kg
during 1 year of renal replacement therapy.
contributing one, in the following order: RRT, serum al-
bumin, age, and gender. In the backward model, in ad-
dition to the presence of diabetes mellitus (B = −2.302,
P < 0.001) and malnutrition (B = 1.265, P = 0.027), in-
flammation was also a significant predictor of LBM loss
(B = −1.321, P = 0.022).
DISCUSSION
In this study we show that incident RRT patients with
diabetes mellitus have accelerated LBM loss as compared
to nondiabetic patients, during the first year of RRT. In
practical terms, if we consider study average values for
serum albumin and age (Table 1), our regression model
predicts that a male patient on RRT, with malnutrition,
inflammation, and presence of diabetes mellitus would
have a LBM loss of about 3.3 kg, as opposed to a LBM loss
of about 1.2 kg for a patient with all the above-mentioned
unfavorable conditions but without diabetes mellitus.
While the current study clearly suggests a relationship
between the development of muscle wasting and the pres-
ence of diabetes mellitus in chronic RRT patients, the
mechanism by which this occurs is not completely un-
derstood. Studies suggest that this difference seems to be
independent of recognized causes of uremic malnutrition
such as inadequate dialysis dose, metabolic acidosis, and
insufficient dietary protein intake [2, 7], indicating that
other mechanisms related to diabetes mellitus and/or ure-
mia contribute to the observed rate of accelerated LBM
loss in diabetic chronic RRT patients. Diabetic patients
are known to have gastrointestinal dysfunction due to
gastroparesis as well as abnormal insulin action inher-
ently related to diabetes mellitus. Indeed, in diabetic pa-
tients without advanced kidney disease, poorly controlled
diabetes mellitus is associated with increased rates of
net protein depletion, potentially due to deficiency or
resistance to the anabolic actions of insulin [8]. Stud-
ies have demonstrated pronounced muscle catabolism
in type 1, insulin-deprived diabetic patients, which can
be reversed with tight glucose control [7, 9], while the
available literature does not indicate any dramatic mus-
cle alterations for type 2 diabetes mellitus, noninsulin-
dependent, regardless of treatment [10, 11]. In addition
to these observations, a recent study by our group show
increased muscle protein breakdown rates in type 2 di-
abetes mellitus (five out of six were insulin-dependent)
hemodialysis patients when compared to age-, gender-,
and race-matched hemodialysis patients without diabetes
mellitus [12]. It is possible that the observed unfavorable
muscle protein homeostasis in the acute setting leads to
increased loss of muscle mass and, consequently, LBM, in
ESRD patients with diabetes mellitus. It is important to
note that ESRD patients on RRT present with a unique
form of type 2 diabetes mellitus, which in most cases de-
velop into insulin-dependency within the initial years of
RRT. This makes difficult the comparison of our results
with those with non-RRT patients who either have type 1
diabetes mellitus (insulin-dependent) or type 2 diabetes
mellitus (noninsulin-dependent). In our study, patients
with type 2 diabetes mellitus (most of which were insulin-
dependent) showed a nonstatistically significantly higher
LBM loss during the 12-month study period, in spite of a
numerically lower glycemia and higher insulinemia com-
pared to type 1 diabetes mellitus patients.
In addition, as weight loss is such a common feature
of many inflammatory disorders it has been suggested
that subclinical inflammation is an important compo-
nent of the pathophysiology of muscle wasting [13]. In
the present study, overt inflammation (CRP ≥10 mg/L)
was marginally associated with loss of LBM when ad-
justed for age, gender, serum albumin, and RRT modality,
and significantly associated with LBM loss in the back-
ward elimination procedure. Of note, CRP is a “mov-
ing target” and highly variable in the RRT population,
which may have accounted for its relatively low impact
on LBM loss observed in this study, since multiple CRP
measurements were not available. Proinflammatory cy-
tokines, such as interleukin (IL)-6 and tumor necrosis
factor (TNF), stimulate the breakdown of muscle pro-
tein [14] and the close association between muscle wast-
ing and IL-6 in long-term RRT patients provides evidence
that IL-6 may be associated with muscle wasting also in
patients with advanced chronic renal failure [15]. As hy-
percytokinemia is a common feature of diabetes melli-
tus (especially NIDDM) [16], further studies are needed
to examine whether IL-6 and TNF may be factors con-
tributing to the accelerated wasting in ESRD. However,
it should be noted that in this study the presence of di-
abetes mellitus was the strongest predictor of LBM loss,
independent of the presence or absence of inflammation
(CRP ≥10 mg/L).
The results of this study must be considered with the
following caveats. First, by the longitudinal design, a se-
lection bias may have been introduced. Specifically, the
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Table 4. Predictors of lean body mass (LBM) loss by multiple linear regression analysis
StandardizedUnstandardized
coefficients 95% CI for Bcoefficients
B Standard error Beta P value Lower bound Upper bound
(Constant) 0.127 2.272 0.956 −4.368 4.621
Age years −0.025 0.024 −0.096 0.293 −0.072 0.022
Male gender −0.678 0.550 −0.103 0.220 −1.766 0.410
Serum albumin g/L 0.012 0.050 .021 0.810 −0.087 0.111
RRT modality (hemodialysis vs. peritoneal dialysis) 0.047 0.521 .007 0.928 −0.984 1.077
Inflammation (C-reactive protein ≥10 mg/L) −1.120 0.606 −0.166 0.067 −2.318 0.078
Malnutrition (Subjective Global Assessment ≥2) 1.316 0.585 0.199 0.026 0.158 2.473
Presence of diabetes mellitus −2.075 0.636 −0.281 0.001 −3.333 −0.817
R R2 Adjusted R2 Standard error of the estimate
0.387 0.150 0.104 2.972
The model included LBM loss as the dependent variable, and the following predictors: age, gender, serum albumin, renal replacement modality (RRT) modality
(peritoneal dialysis vs. hemodialysis), presence of malnutrition at baseline by predefined Subjective Global Assessment categories, presence of inflammation at baseline
(C-reactive protein ≥10 mg/L), and the presence of diabetes mellitus.
123 patients evaluated at baseline who did not com-
plete the study for various reasons displayed significantly
higher proportions of diabetes mellitus, CVD, and ev-
idence of inflammation. Based on these parameters, it
is reasonable to conclude that they constituted a sicker
population and that our results could have been differ-
ent if they had been evaluated. It could be speculated
that the unavoidable exclusion of this sicker group of pa-
tients introduced a negative bias toward our findings as
it would be more unlikely to find a worsening in nutri-
tional parameters in a healthier patient population. On
the other hand, the 29 patients that were not reevaluated
due to transplantation are likely to constitute a healthier
population than patients who did complete 12 months of
dialysis. Therefore, future studies are needed to support
our findings. Second, as nutritional status is so strongly as-
sociated with outcome in ESRD it is important to define
which nutritional indicators to use in the clinical setting.
In the present study we utilized changes in body compo-
sition (i.e., LBM and FM) evaluated by DEXA as the pri-
mary nutritional index. Several methods have been used
to monitor LBM in ESRD patients (e.g., anthropomet-
rics, creatinine kinetics, multifrequency bioimpedance,
and DEXA). Although all these methods have significant
limitations, DEXA seems to be the most reliable, espe-
cially if serial measurements are made [17]. However, to
the best of our knowledge, no studies have yet evalu-
ated if LBM, or changes in LBM (by DEXA) predicts
outcome in ESRD. It must also be noted that the estima-
tion of LBM by DEXA may be confounded by changes
in hydration status. Because the majority of LBM con-
sists of fluid, it is possible that diabetics showed increased
LBM loss just because they had more fluid retention than
nondiabetics. Third, as diabetic patients had higher LBM
at baseline (prior to RRT), the increased loss of LBM
during RRT in the diabetic group may, at least in part,
represent the statistical phenomenon “regression toward
the mean.” Finally, as there was no diversity in ethnical
background in this study, the results may not be totally
extrapolated to all different ethnic backgrounds.
CONCLUSION
Diabetic patients on RRT display increased loss of
LBM when compared to nondiabetes mellitus. Indeed,
the presence of diabetes mellitus is the most significant
predictor of LBM loss when a number of clinically rele-
vant factors are included in a multivariate model. This un-
favorable protein homeostasis could explain why chronic
dialysis patients with diabetes mellitus are more prone to
uremic malnutrition than those without diabetes mellitus.
Further studies with and without controlled insulin and
glucose concentrations are needed to explore the mech-
anisms by which diabetic dialysis patients are exposed to
accelerated loss of LBM.
ACKNOWLEDGMENTS
This study is in part supported by the Karolinska Institutes Fund
for Gender-based Research (P.S.), and So¨derbergs Foundation (P.S.),
NIH Grants R01 DK45604 and 1K24 DK62849. Dr. Ikizler is partly
supported by the Norman S. Coplon Award from the Satellite Health
Extramural Research Program. Dr. Pupim is partly supported by the
Marilyn Charitable Trust Young Investigator Grant of the National Kid-
ney Foundation, the Vanderbilt University School of Medicine Clinician
Scientist Award, as part of the Vanderbilt Physician Scientist Develop-
ment Program, and the Norman S. Coplon Award from the Satellite
Health Extramural Research Program.
Reprint requests to Peter Stenvinkel, M.D., Ph.D., Department of Re-
nal Medicine, K56 Karolinska University Hospital at Huddinge, 141 86
Stockholm, Sweden.
E-mail: peter.stenvinkel@klinvet.ki.se
REFERENCES
1. USRDS: The United States Renal Data System. Am J Kidney Dis
42:1–230, 2003
2. CANO NJ, ROTH H, APARICIO M, et al: Malnutrition in hemodialysis
diabetic patients: Evaluation and prognostic influence. Kidney Int
62:593–601, 2002
2374 Pupim et al: Muscle loss in diabetic dialysis patients
3. STENVINKEL P, HEIMBU¨RGER O, PAULTRE F, et al: Strong association
between malnutrition, inflammation, and atherosclerosis in chronic
renal failure. Kidney Int 55:1899–1911, 1999
4. STENVINKEL P, WANNER C, METZGER T, et al: Inflammation and out-
come in end-stage renal failure: Does female gender constitute a
survival advantage? Kidney Int 62:1791–1798, 2002
5. DETSKY AS, MCLAUGHLIN JR, BAKER JP, et al: What is subjective
global assessment of nutritional status? J Parent Enteral Nutri 11:8–
13, 1987
6. QURESHI AR, ALVESTRAND A, DANIELSSON A, et al: Factors predict-
ing malnutrition in hemodialysis patients: A cross-sectional study.
Kidney Int 53:773–782, 1998
7. CHARLTON M, NAIR KS: Protein metabolism in insulin-dependent
diabetes mellitus. J Nutr 128:323S–327S, 1998
8. FLAKOLL PJ, JENSEN MD, CHERRINGTON AC: Physiologic action of in-
sulin, in Diabetes Mellitus: A Fundamental and Clinical Text, 3rd ed.,
edited by Olefsky J, Philadelphia, Lippincott Williams & Wilkins,
2004, pp 165–181
9. NAIR KS, HALLIDAY D, MATTHEWS DE, et al: Hyperglucagonemia
during insulin deficiency accelerates protein catabolism. Am J Phys-
iol Endocrinol Metab 253:E208–E213, 1987
10. DENNE SC, BRECHTEL G, JOHNSON A, et al: Skeletal muscle prote-
olysis is reduced in noninsulin-dependent diabetes mellitus and is
unaltered by euglycemic hyperinsulinemia or intensive insulin ther-
apy. J Clin Endocrinol Metab 80:2371–2377, 1995
11. HALVATSIOTIS PG, TURK D, ALZAID A, et al: Insulin effect on leucine
kinetics in type 2 diabetes mellitus. Diabetes Nutr Metab 15:136–142,
2002
12. PUPIM LB, FLAKOLL PJ, MAJCHRZAK KM, et al: Increased muscle
protein breakdown in chronic hemodialysis patients with type 2
diabetes mellitus. Kidney Int (in press) 2005
13. ROUBENOFF R: Catabolism of aging: Is it an inflammatory process?
Curr Opin Clin Nutr Metab Care 6:295–299, 2003
14. GOODMAN MN: Interleukin-6 induces skeletal muscle protein break-
down in rats. Proc Soc Exp Biol Med 205:182–185, 1994
15. KAIZU Y, OHKAWA S, ODAMAKI M, et al: Association between in-
flammatory mediators and muscle mass in long-term hemodialysis
patients. Am J Kidney Dis 42:295–302, 2003
16. PEDERSEN M, BRUUNSGAARD H, WEIS N, et al: Circulating levels of
TNF-alpha and IL-6-relation to truncal fat mass and muscle mass
in healthy elderly individuals and in patients with type-2 diabetes.
Mech Ageing Dev 124:495–502, 2003
17. KERR PG, STRAUSS BJ, ATKINS RC: Assessment of the nutritional
state of dialysis patients. Blood Purif 14:382–387, 1996
